TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
AR042052A1
(en)
*
|
2002-11-15 |
2005-06-08 |
Vertex Pharma |
USEFUL DIAMINOTRIAZOLS AS INHIBITORS OF PROTEINQUINASES
|
CA2525547C
(en)
|
2003-05-14 |
2012-07-03 |
Torreypines Therapeutics, Inc. |
Compounds and uses thereof in modulating amyloid beta
|
EP1636215B1
(en)
*
|
2003-05-23 |
2008-01-23 |
Basilea Pharmaceutica AG |
Furazanobenzimidazoles
|
CA2533377C
(en)
*
|
2003-07-30 |
2012-11-27 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
|
WO2005077939A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Basilea Pharmaceutica Ag |
Substituted benzimidazoles and their use for inducing apoptosis
|
JP2007522213A
(en)
*
|
2004-02-11 |
2007-08-09 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Method for producing substituted triazole compounds
|
DK1791830T3
(en)
*
|
2004-09-17 |
2011-04-18 |
Vertex Pharma |
Diaminotriazole compounds useful as protein kinase inhibitors
|
AU2012205127B2
(en)
*
|
2004-09-17 |
2014-10-30 |
Vertex Pharmaceuticals Incorporated |
Diaminotriazole Compounds Useful as Protein Kinase Inhibitors
|
US7888380B2
(en)
|
2004-10-08 |
2011-02-15 |
Janssen Pharmaceutica, N.V. |
1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives
|
US7354944B2
(en)
|
2004-10-18 |
2008-04-08 |
Amgen Inc. |
Thiadiazole compounds and methods of use
|
DE602005024293D1
(en)
*
|
2004-10-21 |
2010-12-02 |
Vertex Pharma |
TRIAZOLE AS AN INHIBITOR OF PROTEIN KINASES
|
JP2008520612A
(en)
*
|
2004-11-24 |
2008-06-19 |
ノバルティス アクチエンゲゼルシャフト |
Combination of JAK inhibitor and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitor
|
PL2559690T3
(en)
|
2005-05-10 |
2016-09-30 |
|
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
RU2485106C2
(en)
|
2005-06-08 |
2013-06-20 |
Райджел Фамэсьютикэлз, Инк. |
Compounds exhibiting jak-kinase activity (versions), method of treating jak-kinase mediated diseases, method of inhibiting jak-kinase activity (versions), pharmaceutical composition of said compounds
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US7825244B2
(en)
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US8071768B2
(en)
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
WO2006135915A2
(en)
|
2005-06-13 |
2006-12-21 |
Rigel Pharmaceuticals, Inc. |
Methods and compositions for treating degenerative bone disorders
|
DE602005000514T2
(en)
*
|
2005-06-17 |
2007-10-25 |
Magneti Marelli Powertrain S.P.A. |
Fuel injector
|
EP2336122B1
(en)
*
|
2005-07-26 |
2014-05-14 |
Vertex Pharmaceuticals Inc. |
1-pyrimidinyl- or 1-pyridinyl-2-amino benzimidazole derivatives and related compounds as inhibitors of protein kinases for the treatment of cancer
|
US7884119B2
(en)
|
2005-09-07 |
2011-02-08 |
Rigel Pharmaceuticals, Inc. |
Triazole derivatives useful as Axl inhibitors
|
CA2621261C
(en)
|
2005-09-22 |
2014-05-20 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
AU2006304897B2
(en)
|
2005-10-18 |
2012-07-12 |
Janssen Pharmaceutica N.V. |
Method of inhibiting FLT3 kinase
|
PL2474545T3
(en)
|
2005-12-13 |
2017-04-28 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
MY149143A
(en)
|
2006-01-18 |
2013-07-15 |
Amgen Inc |
Thiazole compounds as protien kinase b (pkb) inhibitors
|
WO2007098507A2
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
SI2021335T1
(en)
|
2006-04-20 |
2011-09-30 |
Janssen Pharmaceutica Nv |
Heterocyclic compounds as inhibitors of c-fms kinase
|
EP2016070B1
(en)
|
2006-04-20 |
2016-01-13 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
US20080021217A1
(en)
*
|
2006-07-20 |
2008-01-24 |
Allen Borchardt |
Heterocyclic inhibitors of rho kinase
|
US8202876B2
(en)
|
2006-10-02 |
2012-06-19 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
WO2008049123A2
(en)
|
2006-10-19 |
2008-04-24 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
|
US8513270B2
(en)
|
2006-12-22 |
2013-08-20 |
Incyte Corporation |
Substituted heterocycles as Janus kinase inhibitors
|
JP5567837B2
(en)
*
|
2006-12-29 |
2014-08-06 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
N3-heteroaryl-substituted triazoles and N5-heteroaryl-substituted triazoles useful as Axl inhibitors
|
CA2946305C
(en)
*
|
2006-12-29 |
2019-09-17 |
Rigel Pharmaceuticals, Inc. |
Substituted triazoles useful as axl inhibitors
|
JP5546250B2
(en)
|
2006-12-29 |
2014-07-09 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
|
AU2014200825B2
(en)
*
|
2006-12-29 |
2016-05-26 |
Rigel Pharmaceuticals, Inc. |
N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
|
AU2014200824B2
(en)
*
|
2006-12-29 |
2016-12-15 |
Rigel Pharmaceuticals, Inc. |
Substituted triazoles useful as Axl inhibitors
|
AU2016259396B2
(en)
*
|
2006-12-29 |
2018-11-08 |
Rigel Pharmaceuticals, Inc. |
Substituted triazoles useful as Axl inhibitors
|
EP2114954B1
(en)
|
2006-12-29 |
2013-02-13 |
Rigel Pharmaceuticals, Inc. |
Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
|
DK2114955T3
(en)
|
2006-12-29 |
2013-05-06 |
Rigel Pharmaceuticals Inc |
BRIDGED, BICYCLIC ARYL AND BRIDGED, BICYCLIC HETEROARYL SUBSITIATED TRIAZOLES USED AS AXL INHIBITORS
|
JP5642973B2
(en)
*
|
2007-03-22 |
2014-12-17 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
N-heterocyclic compounds useful as JAK inhibitors
|
HUE043732T2
(en)
|
2007-06-13 |
2019-09-30 |
Incyte Holdings Corp |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
CL2008001709A1
(en)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
|
MX2009013782A
(en)
*
|
2007-06-15 |
2010-02-01 |
Irm Llc |
Protein kinase inhibitors and methods for using thereof.
|
AU2008276512A1
(en)
|
2007-07-17 |
2009-01-22 |
Amgen Inc. |
Thiadiazole modulators of PKB
|
AU2008276521B2
(en)
*
|
2007-07-17 |
2011-11-03 |
Amgen Inc. |
Heterocyclic modulators of PKB
|
CA2736563C
(en)
|
2007-09-10 |
2016-01-26 |
Boston Biomedical, Inc. |
A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
|
US20090082470A1
(en)
*
|
2007-09-24 |
2009-03-26 |
Rafal Farjo |
Stat3 inhibiting compositions and methods
|
JO3240B1
(en)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
Inhibitors of c-fms Kinase
|
CN101827836B
(en)
*
|
2007-10-18 |
2014-02-19 |
詹森药业有限公司 |
Trisubstituted 1,2,4-triazoles
|
JO2784B1
(en)
*
|
2007-10-18 |
2014-03-15 |
شركة جانسين فارماسوتيكا ان. في |
1,3,5-trisubstitued triazole derivative
|
WO2009054864A1
(en)
*
|
2007-10-26 |
2009-04-30 |
Rigel Pharmaceuticals, Inc. |
Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
|
CA2703519C
(en)
*
|
2007-11-09 |
2017-04-18 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
WO2009065132A1
(en)
*
|
2007-11-16 |
2009-05-22 |
Oklahoma Medical Research Foundation |
Predicting and diagnosing patients with autoimmune disease
|
ES2569528T3
(en)
|
2007-11-16 |
2016-05-11 |
Incyte Holdings Corporation |
4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as Janus kinase inhibitors
|
AU2009214440B2
(en)
|
2008-02-15 |
2014-09-25 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
|
AU2009223640B2
(en)
|
2008-03-11 |
2013-07-04 |
Incyte Holdings Corporation |
Azetidine and cyclobutane derivatives as jak inhibitors
|
ES2546502T3
(en)
|
2008-04-16 |
2015-09-24 |
Portola Pharmaceuticals, Inc. |
2,6-Diamino-pyrimidin-5-yl-carboxamides as inhibitors of syk or JAK kinases
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
CA2723185A1
(en)
*
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
JP2011518836A
(en)
|
2008-04-24 |
2011-06-30 |
インサイト・コーポレイション |
Macrocycles and their use as kinase inhibitors
|
EP2288260A4
(en)
*
|
2008-06-20 |
2013-10-23 |
Genentech Inc |
Triazolopyridine jak inhibitor compounds and methods
|
CN102131390A
(en)
*
|
2008-06-20 |
2011-07-20 |
健泰科生物技术公司 |
Triazolopyridine jak inhibitor compounds and methods
|
DK2824100T3
(en)
|
2008-07-08 |
2018-04-16 |
Incyte Holdings Corp |
1,2,5-oxadiazoles as inhibitors of indolamine-2,3-dioxygenase
|
PT2328888E
(en)
|
2008-07-09 |
2013-01-29 |
Rigel Pharmaceuticals Inc |
Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
|
JP5592884B2
(en)
*
|
2008-07-09 |
2014-09-17 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors
|
KR101696936B1
(en)
*
|
2008-07-10 |
2017-01-16 |
잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 |
Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
|
TWI453207B
(en)
*
|
2008-09-08 |
2014-09-21 |
Signal Pharm Llc |
Aminotriazolopyridines, compositions thereof, and methods of treatment therewith
|
JP2012502882A
(en)
*
|
2008-09-18 |
2012-02-02 |
アステラス製薬株式会社 |
Heterocyclic carboxamide compounds
|
CL2009001884A1
(en)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
|
EP2370580B1
(en)
*
|
2008-12-04 |
2019-09-11 |
CuRNA, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
|
CN105399731A
(en)
*
|
2008-12-24 |
2016-03-16 |
比亚尔-珀特拉和Ca股份公司 |
Pharmaceutical Compounds
|
RU2555326C2
(en)
*
|
2009-01-16 |
2015-07-10 |
Риджел Фармасьютикалз, Инк. |
Axl INHIBITORS APPLICABLE IN COMBINATION THERAPY FOR PREVENTING, RELIEVING OR TREATING METASTATIC CANCER
|
US8765727B2
(en)
|
2009-01-23 |
2014-07-01 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
WO2010105243A1
(en)
|
2009-03-13 |
2010-09-16 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
CA2761954C
(en)
|
2009-05-22 |
2018-07-31 |
Incyte Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
AU2010249380B2
(en)
|
2009-05-22 |
2015-08-20 |
Incyte Holdings Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
|
KR101444559B1
(en)
*
|
2009-06-09 |
2014-09-26 |
액테리온 파마슈티칼 리미티드 |
Fluorinated aminotriazole derivatives
|
CA2766100C
(en)
|
2009-06-29 |
2018-05-22 |
Incyte Corporation |
Pyrimidinones as pi3k inhibitors
|
NZ597379A
(en)
|
2009-06-29 |
2014-04-30 |
Agios Pharmaceuticals Inc |
Therapeutic compounds and compositions
|
RU2557982C2
(en)
*
|
2009-07-28 |
2015-07-27 |
Райджел Фармасьютикалз, Инк. |
Compositions and methods for jak path inhibition
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
CN102596960B
(en)
|
2009-10-09 |
2016-01-20 |
因西特控股公司 |
The hydroxy derivatives of 3-(4-(7H-pyrrolo-[2,3-d] pyrimidine-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl propionitrile, ketone group derivative and glucuronide
|
CA2793835C
(en)
|
2009-10-21 |
2021-07-20 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
TW201130842A
(en)
|
2009-12-18 |
2011-09-16 |
Incyte Corp |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
US9109227B2
(en)
|
2010-01-05 |
2015-08-18 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
FLT3 receptor antagonists for the treatment or the prevention of pain disorders
|
SG182480A1
(en)
|
2010-01-12 |
2012-08-30 |
Ab Science |
Thiazole and oxazole kinase inhibitors
|
WO2011091153A1
(en)
*
|
2010-01-25 |
2011-07-28 |
Chdi, Inc. |
Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
|
EA023444B1
(en)
|
2010-02-18 |
2016-06-30 |
Инсайт Холдингс Корпорейшн |
Cyclobutane and methylcyclobutane derivatives, composition based thereon and methods of use thereof
|
AR081315A1
(en)
|
2010-03-10 |
2012-08-08 |
Incyte Corp |
HETEROCICLIC DERIVATIVES OF PIPERIDIN AND PIRIMIDIN -4-IL-AZETIDINA, A CRYSTALLINE FORM OF THE SALT OF ACETONITRILADIPICO ACID OF A PYRIMIDINIC DERIVATIVE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME THINGS WITH THE TREATMENT OF INJECTION , T
|
CA2959931A1
(en)
*
|
2010-03-19 |
2011-09-22 |
Boston Biomedical, Inc. |
Naphthofuran compounds and compositions for targeting cancer stem cells
|
WO2011116399A1
(en)
|
2010-03-19 |
2011-09-22 |
Boston Biomedical, Inc. |
Novel methods for targeting cancer stem cells
|
AU2011232372B2
(en)
*
|
2010-03-24 |
2016-06-30 |
Amitech Therapeutic Solutions, Inc. |
Heterocyclic compounds useful for kinase inhibition
|
EP2558463A1
(en)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Fused derivatives as i3 inhibitors
|
NZ603686A
(en)
|
2010-05-21 |
2014-11-28 |
Incyte Corp |
Topical formulation for a jak inhibitor
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
JP2012102090A
(en)
*
|
2010-10-15 |
2012-05-31 |
Sumitomo Chemical Co Ltd |
Pyrimidine compound and use thereof for harmful organism control
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
JP5917544B2
(en)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
EA026201B1
(en)
|
2010-11-19 |
2017-03-31 |
Инсайт Холдингс Корпорейшн |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
TW201249844A
(en)
|
2010-12-20 |
2012-12-16 |
Incyte Corp |
N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
|
PL2675451T3
(en)
|
2011-02-18 |
2016-05-31 |
Novartis Pharma Ag |
mTOR/JAK INHIBITOR COMBINATION THERAPY
|
AU2012243226A1
(en)
*
|
2011-03-01 |
2013-09-26 |
Npharmakon, Llc |
Use of N-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine and related compounds
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
HUE039269T2
(en)
|
2011-05-03 |
2018-12-28 |
Agios Pharmaceuticals Inc |
Pyruvate kinase activators for use in therapy
|
CN102827073A
(en)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
Therapeutically active compositions and application methods thereof
|
CN102827170A
(en)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
Active treatment compositions and use method thereof
|
AR086983A1
(en)
|
2011-06-20 |
2014-02-05 |
Incyte Corp |
DERIVATIVES OF AZETIDINIL FENIL, PIRIDIL OR PIRAZINIL CARBOXAMIDA AS JAK INHIBITORS
|
WO2013023119A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
JAK P13K/mTOR COMBINATION THERAPY
|
TW201313721A
(en)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
Cyclohexyl azetidine derivatives as JAK inhibitors
|
EP3243515B1
(en)
|
2011-08-30 |
2019-10-16 |
CHDI Foundation, Inc. |
Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
|
WO2013033068A1
(en)
|
2011-08-30 |
2013-03-07 |
Stephen Martin Courtney |
Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
|
IL299533A
(en)
|
2011-09-02 |
2023-02-01 |
Incyte Holdings Corp |
Heterocyclylamines as pi3k inhibitors
|
UA111854C2
(en)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
|
WO2013049591A2
(en)
*
|
2011-09-29 |
2013-04-04 |
Verseon Corporation |
Dual inhibitor compounds and methods of use thereof
|
EA026939B1
(en)
|
2011-11-23 |
2017-06-30 |
Портола Фармасьютикалз, Инк. |
Pyrazine kinase inhibitors
|
UA117451C2
(en)
|
2012-01-06 |
2018-08-10 |
Аджиос Фармасьютікалз, Інк. |
Therapeutically active compounds and their methods of use
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
WO2013122575A2
(en)
*
|
2012-02-14 |
2013-08-22 |
Grl |
Small molecule having antiviral properties
|
AR090548A1
(en)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
|
MY184577A
(en)
|
2012-05-08 |
2021-04-06 |
Bayer Pharma AG |
Method for the preparation of triazole compounds
|
AR091079A1
(en)
|
2012-05-18 |
2014-12-30 |
Incyte Corp |
DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
|
DK3176170T3
(en)
|
2012-06-13 |
2019-01-28 |
Incyte Holdings Corp |
SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS
|
US20140010783A1
(en)
*
|
2012-07-06 |
2014-01-09 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
WO2014011540A1
(en)
*
|
2012-07-09 |
2014-01-16 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
JOP20180012A1
(en)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
Sulfonylation process using nonafluorobutanesulfonyl fluoride
|
WO2014025675A1
(en)
|
2012-08-07 |
2014-02-13 |
Janssen Pharmaceutica Nv |
Process for the preparation of heterocyclic ester derivatives
|
TWI569799B
(en)
|
2012-09-21 |
2017-02-11 |
安羅格製藥股份有限公司 |
Method of inhibiting constitutively active phosphorylated flt3 kinase
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
MX365747B
(en)
|
2012-10-15 |
2019-06-12 |
Agios Pharmaceuticals Inc |
Therapeutic compounds and compositions.
|
EA031882B1
(en)
|
2012-11-01 |
2019-03-29 |
Инсайт Холдингс Корпорейшн |
Tricyclic fused thiophene derivatives as jak inhibitors
|
PL2919766T3
(en)
|
2012-11-15 |
2021-10-04 |
Incyte Holdings Corporation |
Sustained-release dosage forms of ruxolitinib
|
BR112015016282A2
(en)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals Inc |
crenolanib for treatment of mutated flt3 proliferative disorders
|
TWI687220B
(en)
|
2013-03-01 |
2020-03-11 |
美商英塞特控股公司 |
Use of pyrazolopyrimidine derivatives for the treatment of pi3kδ related disorders
|
US9896433B2
(en)
*
|
2013-03-05 |
2018-02-20 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
WO2014135471A1
(en)
*
|
2013-03-05 |
2014-09-12 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
AU2014225938B2
(en)
|
2013-03-06 |
2018-07-19 |
Incyte Holdings Corporation |
Processes and intermediates for making a JAK inhibitor
|
CA2898107A1
(en)
|
2013-03-06 |
2014-09-12 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
RU2015147696A
(en)
|
2013-04-09 |
2017-05-12 |
Бостон Байомедикал, Инк. |
METHODS FOR TREATING A MALIGNANT TUMOR
|
ES2893725T3
(en)
|
2013-04-19 |
2022-02-09 |
Incyte Holdings Corp |
Bicyclic heterocyclics as FGFR inhibitors
|
FI3786162T3
(en)
|
2013-05-17 |
2023-10-02 |
Incyte Holdings Corp |
Bipyrazole derivatives as jak inhibitors
|
US10376510B2
(en)
|
2013-07-11 |
2019-08-13 |
Agios Pharmaceuticals, Inc. |
2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
US9579324B2
(en)
|
2013-07-11 |
2017-02-28 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
KR102302091B1
(en)
|
2013-07-11 |
2021-09-16 |
아지오스 파마슈티컬스 아이엔씨. |
N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
|
WO2015003355A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
US20150031627A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
MX2016001639A
(en)
|
2013-08-07 |
2016-10-07 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor.
|
EP3035966A1
(en)
|
2013-08-20 |
2016-06-29 |
Incyte Corporation |
Survival benefit in patients with solid tumors with elevated c-reactive protein levels
|
US10463658B2
(en)
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
HUE041456T2
(en)
|
2014-02-28 |
2019-05-28 |
Incyte Corp |
Jak1 inhibitors for the treatment of myelodysplastic syndromes
|
KR20220070066A
(en)
|
2014-03-14 |
2022-05-27 |
아지오스 파마슈티컬스 아이엔씨. |
Pharmaceutical compositions of therapeutically active compounds
|
MA39984B1
(en)
|
2014-04-08 |
2020-12-31 |
Incyte Corp |
Treatment of malignancies by b lymphocytes with a combined jak and pi3k inhibitor
|
EA201692193A1
(en)
|
2014-04-30 |
2017-07-31 |
Инсайт Корпорейшн |
METHODS OF OBTAINING JAK1 INHIBITOR AND ITS NEW FORMS
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
EP3169684B1
(en)
|
2014-07-17 |
2019-06-26 |
CHDI Foundation, Inc. |
Combination of kmo inhibitor 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid with antiviral agent for treating hiv related neurological disorders
|
CN107001283B
(en)
|
2014-07-31 |
2021-05-25 |
国家健康与医学研究院 |
FLT3 receptor antagonists
|
US9586949B2
(en)
|
2015-02-09 |
2017-03-07 |
Incyte Corporation |
Aza-heteroaryl compounds as PI3K-gamma inhibitors
|
CN107438607B
(en)
|
2015-02-20 |
2021-02-05 |
因赛特公司 |
Bicyclic heterocycles as FGFR inhibitors
|
MA41551A
(en)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
|
HUE060953T2
(en)
|
2015-02-27 |
2023-04-28 |
Incyte Holdings Corp |
Processes for the preparation of a pi3k inhibitor
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
US20160362424A1
(en)
|
2015-05-11 |
2016-12-15 |
Incyte Corporation |
Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
|
SI3307271T1
(en)
|
2015-06-11 |
2023-11-30 |
Agios Pharmaceuticals, Inc. |
Methods of using pyruvate kinase activators
|
BR122024000250A2
(en)
|
2015-10-15 |
2024-02-27 |
Les Laboratoires Servier |
USE OF A MUTANT ISOCITRATE 1 (IDH1) DEHYDROGENASE INHIBITOR AND A DNA DEMETHYLATING AGENT
|
UA123401C2
(en)
|
2015-10-15 |
2021-03-31 |
Аджиос Фармасьютікалз, Інк. |
Combination therapy for treating malignancies
|
MD3371190T2
(en)
|
2015-11-06 |
2022-09-30 |
Incyte Corp |
Heterocyclic compounds as pi3k-gamma inhibitors
|
EP3400221B1
(en)
|
2016-01-05 |
2020-08-26 |
Incyte Corporation |
Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors
|
EP3241830A1
(en)
|
2016-05-04 |
2017-11-08 |
Bayer CropScience Aktiengesellschaft |
Condensed bicyclic heterocyclic derivatives as pesticides
|
EP3254698A1
(en)
|
2016-06-08 |
2017-12-13 |
Universite De Montpellier |
Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
|
WO2017223414A1
(en)
|
2016-06-24 |
2017-12-28 |
Incyte Corporation |
HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
|
AU2017300336B2
(en)
*
|
2016-07-18 |
2021-03-11 |
National Institute Of Biological Sciences, Beijing |
Apoptosis inhibitors
|
EP3359155A4
(en)
|
2016-11-02 |
2019-05-22 |
Arog Pharmaceuticals, Inc. |
Crenolanib for treating flt3 mutated proliferative disorders associated mutations
|
US11299469B2
(en)
|
2016-11-29 |
2022-04-12 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
RU2629360C1
(en)
*
|
2016-12-08 |
2017-08-29 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский технологический университет" |
New 1-(-d-ribofuranosil-3-(5-substituted-1,2,4-oxadiazole-3-yl)-1,2,4-triazoles with anti-viral properties and method for their production
|
JP2020519665A
(en)
|
2017-05-17 |
2020-07-02 |
アンセルム(アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル) |
FLT3 inhibitors for improving opioid pain management
|
US10646464B2
(en)
|
2017-05-17 |
2020-05-12 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
AR111960A1
(en)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia
|
MA50398B1
(en)
|
2017-10-18 |
2021-10-29 |
Incyte Corp |
Condensed imidazole derivatives, substituted by tertiary hydroxy groups, used as inhibitors of pi3k-gamma
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
US11306079B2
(en)
|
2017-12-21 |
2022-04-19 |
Incyte Corporation |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
|
GB201801226D0
(en)
|
2018-01-25 |
2018-03-14 |
Redx Pharma Plc |
Modulators of Rho-associated protein kinase
|
DK3746429T3
(en)
|
2018-01-30 |
2022-05-02 |
Incyte Corp |
PROCEDURES FOR THE PREPARATION OF (1- (3-FLUORO-2- (TRIFLUOROMETHYL) ISONICOTINYL) PIPERIDIN-4-ON)
|
MX2020008521A
(en)
|
2018-02-16 |
2020-12-03 |
Incyte Corp |
Jak1 pathway inhibitors for the treatment of cytokine-related disorders.
|
US20190292188A1
(en)
|
2018-02-27 |
2019-09-26 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
SG11202008560VA
(en)
|
2018-03-08 |
2020-10-29 |
Incyte Corp |
AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
|
UA127925C2
(en)
|
2018-03-30 |
2024-02-14 |
Інсайт Корпорейшн |
Treatment of hidradenitis suppurativa using jak inhibitors
|
WO2019191679A1
(en)
|
2018-03-30 |
2019-10-03 |
Incyte Corporation |
Biomarkers for inflammatory skin disease
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
UA127065C2
(en)
|
2018-04-25 |
2023-03-29 |
Баєр Акціенгезельшафт |
Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
|
MA52493A
(en)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
FGFR INHIBITOR SALTS
|
BR112020022392A2
(en)
|
2018-05-04 |
2021-02-02 |
Incyte Corporation |
solid forms of a fgfr inhibitor and processes for preparing them
|
MX2020012376A
(en)
|
2018-05-18 |
2021-03-09 |
Incyte Corp |
Fused pyrimidine derivatives as a2a / a2b inhibitors.
|
WO2019227007A1
(en)
|
2018-05-25 |
2019-11-28 |
Incyte Corporation |
Tricyclic heterocyclic compounds as sting activators
|
JP7357371B2
(en)
*
|
2018-06-04 |
2023-10-06 |
エイシー イミューン ソシエテ アノニム |
Tetrahydrobenzofuro[2,3-C]pyridine and beta-carboline compounds for the treatment, mitigation, or prevention of disorders associated with tau aggregates
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
AU2019297361A1
(en)
|
2018-07-05 |
2021-02-25 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
US10875872B2
(en)
|
2018-07-31 |
2020-12-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
WO2020028565A1
(en)
|
2018-07-31 |
2020-02-06 |
Incyte Corporation |
Tricyclic heteraryl compounds as sting activators
|
WO2020036133A1
(en)
*
|
2018-08-17 |
2020-02-20 |
クミアイ化学工業株式会社 |
3-(1h-1,2,4-triazole-1-yl) benzoic acid amide derivative and harmful organism control agent
|
SG11202102224UA
(en)
|
2018-09-05 |
2021-04-29 |
Incyte Corp |
Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
WO2020102198A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
WO2020102216A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Substituted heterocyclic derivatives as pi3k inhibitors
|
WO2020102150A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
US20220056049A1
(en)
|
2019-01-07 |
2022-02-24 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
TWI829857B
(en)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
|
JP2022519772A
(en)
|
2019-02-15 |
2022-03-24 |
インサイト・コーポレイション |
Cyclin-dependent kinase 2 biomarker and its use
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
US11602536B2
(en)
|
2019-06-10 |
2023-03-14 |
Incyte Corporation |
Topical treatment of vitiligo by a JAK inhibitor
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
CA3148209A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Aktiengesellschaft |
Novel heteroaryl-triazole compounds as pesticides
|
CN114502545A
(en)
|
2019-07-23 |
2022-05-13 |
拜耳公司 |
Novel heteroaryl-triazole compounds as pesticides
|
AU2020319875A1
(en)
|
2019-08-01 |
2022-02-17 |
Incyte Corporation |
A dosing regimen for an IDO inhibitor
|
JP2023509260A
(en)
|
2019-08-14 |
2023-03-08 |
インサイト・コーポレイション |
Imidazolylpyrimidinylamine compounds as CDK2 inhibitors
|
JP2022545923A
(en)
|
2019-08-26 |
2022-11-01 |
インサイト・コーポレイション |
Triazolopyrimidines as A2A/A2B inhibitors
|
CN115298177A
(en)
|
2019-10-11 |
2022-11-04 |
因赛特公司 |
Bicyclic amines as CDK2 inhibitors
|
CR20220169A
(en)
|
2019-10-14 |
2022-10-27 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
JP2023506118A
(en)
|
2019-10-16 |
2023-02-15 |
インサイト・コーポレイション |
Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (LP)
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
JP2023505258A
(en)
|
2019-12-04 |
2023-02-08 |
インサイト・コーポレイション |
Tricyclic heterocycles as FGFR inhibitors
|
WO2021113462A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
EP4114401A1
(en)
|
2020-03-06 |
2023-01-11 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
IL297165A
(en)
|
2020-04-16 |
2022-12-01 |
Incyte Corp |
Fused tricyclic kras inhibitors
|
GB202006382D0
(en)
|
2020-04-30 |
2020-06-17 |
Spermatech As |
Use
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
KR20230027086A
(en)
|
2020-06-02 |
2023-02-27 |
인사이트 코포레이션 |
Manufacturing process of JAK1 inhibitor
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11713310B2
(en)
|
2020-07-20 |
2023-08-01 |
Arog Pharmaceuticals, Inc. |
Crystal forms of crenolanib and methods of use thereof
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
EP4213800A1
(en)
|
2020-09-16 |
2023-07-26 |
Incyte Corporation |
Topical treatment of vitiligo
|
US11767320B2
(en)
|
2020-10-02 |
2023-09-26 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of KRAS
|
KR20230118118A
(en)
|
2020-12-08 |
2023-08-10 |
인사이트 코포레이션 |
JAK1 pathway inhibitors for the treatment of vitiligo
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
WO2022261160A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
AR126101A1
(en)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
|
WO2023283213A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
CA3224841A1
(en)
|
2021-07-14 |
2023-01-19 |
Zhenwu Li |
Tricyclic compounds as inhibitors of kras
|
US20230174555A1
(en)
|
2021-08-31 |
2023-06-08 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
WO2023056421A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
WO2023064458A1
(en)
*
|
2021-10-13 |
2023-04-20 |
Yale University |
Selective jak2 inhibitors and methods of use
|
CA3235146A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
TW202320792A
(en)
|
2021-11-22 |
2023-06-01 |
美商英塞特公司 |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
WO2023107705A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
WO2023122134A1
(en)
|
2021-12-22 |
2023-06-29 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
TW202341982A
(en)
|
2021-12-24 |
2023-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Cdk2 inhibitors and use thereof
|
WO2023172921A1
(en)
|
2022-03-07 |
2023-09-14 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
US20230399331A1
(en)
|
2022-06-14 |
2023-12-14 |
Incyte Corporation |
Solid forms of jak inhibitor and process of preparing the same
|
WO2023250430A1
(en)
|
2022-06-22 |
2023-12-28 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
WO2024030600A1
(en)
|
2022-08-05 |
2024-02-08 |
Incyte Corporation |
Treatment of urticaria using jak inhibitors
|
WO2024051667A1
(en)
*
|
2022-09-05 |
2024-03-14 |
南京正大天晴制药有限公司 |
Substituted triazole compound having axl inhibitory activity
|